Our Shield™ blood test gains FDA approval, ushering in a new era of colorectal cancer screening.  More details

Colorectal cancer screening made easy.

Whether it’s a screening event or an offering through your workplace clinic, Shield™ can be easily integrated into your organization.

Host a screening event

From planning to recruiting to handling the blood draws, Guardant Health will work with you to make sure your Shield™ colorectal cancer (CRC) screening day goes off without a hitch!

Guidance for Screening Program

Employee Communication Tools

Co-Branded Platform: Pre-qualification & Scheduling*

Appointment Reminder*

Physician & Phlebotomy Services*

Blood Collection Kits

Reporting: Employee Engagement and Outcomes

Ongoing Support

*services provided by an independent third-party contracted by Guardant Health

Implementing your screening day is as easy as:

1

Planning

2

Prepping and design

3

Recruitment

4

Employee screening day

Implementing your worksite health clinic:

Offer through your worksite health clinic

From training and support to tools and resources, Guardant Health will work with you to make sure Shield™ is seamlessly implemented into your worksite health clinic.

*services provided by an independent third-party contracted by Guardant Health

Easily integrated

1
GuardantGo
Activation
2
Worksite clinic
in-service
(training)
3
Order
product
4
Start
screening

Let us help you promote Shield™

Whichever program you choose, we will provide branded awareness, education and promotional support materials.

  • Launch emails

  • Social media graphics

  • Postcard mailers

  • Recruitment flyers

  • Platform managing recruitment, eligibility, and scheduling

Simply done.

Learn more about how you can bring Shield™ to your company and help increase CRC screening compliance.

Contact Us
Shield™ is a qualitative laboratory developed test intended to detect colorectal neoplasia by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
  • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
  • Patients with an “abnormal signal detected” Shield result should be referred for colonoscopic evaluation
  • A “normal signal detected” Shield result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
  • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
References 1. 1 ACS 2018 (BRFSS) 2. American Society of Clinical Oncology. Colorectal cancer: statistics. Cancer.net website. Updated January 2021. Accessed May 10, 2021. https://www.cancer.net/cancer-types/colorectal-cancer/statistics 3. National Cancer Institute. Colon and rectum stage distribution of SEER incidence cases, 2009-2018. Accessed November 10, 2021. https://seer.cancer.gov/explorer/application.html?site=20&data_type=1&graph_type=&compareBy=sex&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1 4. Centers for Disease Control and Prevention. Cost-effectiveness of colorectal cancer interventions. Updated August 18, 2021. Accessed December 7, 2021. https://www.cdc.gov/chronicdisease/programs-impact/pop/colorectal-cancer.htm 5. American Society of Clinical Oncology. Colorectal cancer: statistics. Cancer.net website. Updated January 2021. Accessed May 10, 2021. https://www.cancer.net/cancer-types/colorectal-cancer/statistics 6. Centers for Disease Control and Prevention. No Time for Guesswork. Accessed May 8, 2023 https://www.cdc.gov/screenoutcancer/pdf/no-time-guesswork-508.pdf 7. Shield LDT Internal Data 8. EXACT Sciences Q2 2022 Earnings 9. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. Ann Intern Med. 2016;164(7):456–63 10. Bretthauer M, Loberg M, Wieszczy P, et al: Effect of colonoscopy screening on risks of colorectal cancer and related death. 11. Data on File. Guardant Health. 12 Guardant Health. Q3 2022 Earnings Call. Accessed November 30, 2022.